A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
for
Metastatic Colorectal Cancer
Location: Boston MA, New Haven CT, Montreal, Fairfax VA,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06820463
Phase2, Recruiting
Featured
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
for
Moderately to Severely Active Crohns Disease
Location: Providence RI, North Worcester MA, Lebanon NH,
Sponsor: Hoffmann-La Roche
Sex: All
Age: 16 - 70+
Code: NCT06819891
Phase3, Recruiting
Featured
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
for
Non-Small Cell Lung Cancer, c-MET
Location: New Haven CT, Westbury NY, The Bronx NY, Teaneck NJ,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT06568939
Phase2, Recruiting
Featured
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
for
Non-small Cell Lung Cancer
Location: Boston MA, New Haven CT, Lebanon NH, New York NY,
Sponsor: Genentech, Inc.
Sex: All
Age: 18+
Code: NCT04302025
Phase2, Recruiting
Featured
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
for
Juvenile Idiopathic Arthritis
Location: Valhalla NY, Washington D.C. DC, Cincinnati OH,
Sponsor: AbbVie
Sex: All
Age: 1 - 17
Code: NCT05609630
Phase3, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Featured
Observational Study to Assess Adverse Events When Adult Female Participants Are Treated With Ubrelvy (Ubrogepant) or Qulipta (Atogepant) During Pregnancy
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
for
Ovarian Cancer
Location: Fairfax VA, Chicago IL, Omaha NE, San Antonio TX,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07278336
Phase1, Recruiting
Featured
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
for
Crohn's Disease, Ulcerative Colitis
Location: New Bedford MA, Providence RI, New York NY, Richmond VA,
Sponsor: AbbVie
Sex: All
Age: 18 - 70+
Code: NCT07697456
Phase2, Recruiting
Featured
Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson Disease
for
Parkinson's Disease
Location: Georgetown TX
Sponsor: AbbVie
Sex: All
Age: 18 - 70+
Code: NCT07227896
Recruiting
Featured
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
for
Atopic Dermatitis
Location: Minneapolis MN
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT07223697
Phase2, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
for
Non-Small Cell Lung Cancer, c-MET
Location: Lebanon NH, East Brunswick NJ, Rockledge FL, Brampton,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07155187
Phase2, Phase3, Recruiting
Featured
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
for
Small Cell Lung Cancer
Location: Boston MA, Mullica Hill NJ, Bethlehem PA, Fairfax VA,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07365241
Phase3, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
for
Acute Myeloid Leukemia
Location: The Bronx NY, Tampa FL, Atlanta GA, St Louis MO,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07581002
Phase2, Phase3, Recruiting
Featured
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
for
Early Breast Cancer
Location: Sterling Heights MI, Fountain Valley CA
Sponsor: Genentech, Inc.
Sex: Female
Age: 18+
Code: NCT07541079
Phase3, Recruiting
Featured
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
for
Active Ulcerative Colitis
Location: Miami FL, Chula Vista CA
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18 - 60
Code: NCT07665723
Phase1, Recruiting
Featured
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
for
Advanced Prostate Cancer, Metastatic Prostate Cancer
Location: Nashville TN, Scottsdale AZ
Sponsor: Genentech, Inc.
Sex: Male
Age: 18+
Code: NCT07567846
Phase1, Phase2, Recruiting
Featured
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
for
Metastatic Pancreatic Ductal Adenocarcinoma, PDAC
Location: New Haven CT, Philadelphia PA, Fairfax VA, Cleveland OH,
Sponsor: AbbVie
Sex: All
Age: 18+
Code: NCT07490301
Phase2, Phase3, Recruiting
Featured
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
for
Ovarian Cancer
Location: Scarborough ME, Worcester MA, New York NY, Camden NJ,
Sponsor: AbbVie
Sex: Female
Age: 18+
Code: NCT07059845
Phase2, Recruiting
Featured
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)